Coloplast stock
COLO-B.COCPHColoplast A/S, HealthcareISIN DK0060448595
69Score 69 out of 100, Neutral
Price and trend
80 / 100
Price history
−18% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 19% below its 52-week high. Largest decline in 20 years: 69% (August 2021 to June 2026).
Chart figures for advanced users
- SMA 50$67.03
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$64.94
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$55.19
- The lowest closing price of the last twelve months.
- Resistance$90.93
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Coloplast A/S belongs to the Medical (Instruments & Supplies) industry (Denmark) and, with a market value of $16.51B, is number 11 of 44 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $4.29B (up 3.8% year on year) and earnings of $455.67M (down 15.5%).
- For fiscal 2027, analysts expect on average revenue of $4.63B (up 7.8%) and adjusted earnings per share of $3.79 (up 3.9%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 151 of 702 in Healthcare, median 53.
- Our model puts fair value at $83.00, with the price 12% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 215% of earnings over the last 12 months.Fundamentals 94
- Reliable dividendNo dividend cut for 17 years.Capital allocation 63
- High dividend yieldDividend yield 4.65%, Medical (Instruments & Supplies) median 0.87%.Capital allocation 63
Weaknesses
- High debtDebt 1.51 times equity (latest quarter), Medical (Instruments & Supplies) median 0.45.Stability 56
Its standout strengths are fundamentals and technical analysis, while growth holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $63.85 and expensive above $118.57 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $68.66, at 6.2% it would be $104.56.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 3.8% on the prior year. Revenue has grown solidly since 2007, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 67%, operating 25%, net 11%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 9 Feb 2027in 88 days
- Last reported
- 2 Nov 2026EPS reported $0.84 (expected $0.88)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.79−2.7%
- Revenue
- $4.63B+1.0%
- Earnings per share
- $4.08−2.7%
- Revenue
- $4.92B+1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: +4.9%The outlook for Kerecis is now lower and the US launch of Intibia is pushed to 2027 or 2028, with limited impact on sales.
“Distribution costs grew 2% versus last year, reflecting Kerecis one-off cost in Q1, partly offset by lower sales costs in China and lower logistics costs due to the one-off cost in the U.S. last year. Lower financial items also had a positive impact on cash flows, while higher income tax paid had a negative impact.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 18 Aug 2026 (fiscal Q3 2026), read by AI.
What happened at Coloplast
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- West Pharmaceutical ServicesWST $28.65B77
- Sartorius Stedim BiotechDIM.PA $24.02B58
- Straumann HoldingSTMN.SW $20.53B78
- SartoriusSRT.DE $17.33B59
- SolventumSOLV $15.09B61
- Baxter InternationalBAX $13.32B47
- Cooper CompaniesCOO $11.83B61
- RepligenRGEN $10.64B50
ETFs that hold Coloplast
Held by 117 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI Europe Quality Dividend Advanced UCITS ETFQDVX | 0.79% | 0.28% | €959.8M |
| Fidelity Europe Quality Income UCITS ETF INC-EURFEUI | 0.77% | 0.30% | €75.69M |
| WisdomTree Europe Equity Income UCITS ETFWTEE | 0.71% | 0.29% | €241.09M |
Show 5 more
| iShares Edge MSCI Europe Minimum Volatility UCITS ETFEUN0 | 0.66% | 0.25% | €991.48M |
| Xtrackers MSCI Nordic UCITS ETF 1DXDN0 | 0.65% | 0.30% | €1.19B |
| iShares STOXX Europe Mid 200 UCITS ETF (DE)EXSD | 0.63% | 0.20% | €634.13M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 0.58% | 0.46% | €722.41M |
| iShares MSCI Europe Mid-Cap Equal Weight UCITS ETFCEMT | 0.56% | 0.25% | €36.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.